Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies
About the study
Phase 1 2-part study to evaluate the effect of food on pharmacokinetics of pelabresib (CPI-0610) and the effect of pelabresib on QTc in patients with advanced malignancies
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- 18 years of age or older
- Confirmed diagnosis of an advanced malignancy for which no effective standard treatment options are available
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤2
EXCLUSION CRITERIA
Exclusion Criteria:
Chronic or active conditions and/or concomitant medication use that would prohibit treatment
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Advanced Malignancies,Solid Tumor,Hematological Malignancy
Age (in years)
18+
Phase
Phase 1
Participants needed
32
Est. Completion Date
Nov 15, 2023
Treatment type
Interventional
Sponsor
Constellation Pharmaceuticals
ClinicalTrials.gov identifier
NCT05391022
Study number
CPI 0610-05
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?